Get into the groove! Targeting antigens to MHC class II

Immunological Reviews

Volumn 172, Issue , 1999, Pages 87-96

  Van Bergen, Jeroen ^a   Ossendorp, Ferry ^a   Jordens, Reina ^a   Mommaas, A Mieke ^a   Drijfhout, Jan Wouter ^a   Koning, Frits ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; DNA SEQUENCE; GENE CONSTRUCT; HELPER CELL; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0033404987     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065x.1999.tb01358.x     Document Type: Article

References (55)

1. 1. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the MHC class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
2. 2. Wubbolts R, et al. Direct vesicular transport of MHC class II molecules from lysosomal structures to the cell surface. J Cell Biol 1996;135:611-622.
3. 3. Colomb MG, Villiers CL, Villiers M-B, Gabert FM, Santoro L, Rey-Millet CA. The role of antigen-bound C3b in antigen processing. Res Immunol 1996;147:75-82.
4. 4. Dempsey PW, Allisson MED, Akkaraju S, Goodnow CC, Fearon D. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996;271:348-350.
5. 5. Tan MCAA, et al. Mannose-receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 1997;27:2426-2435.
6. 6. Engering AJ, et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 1997;27:2417-2425.
7. 7. Platt N, da Silva RP, Gordon S. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol 1998;8:365-372.
8. 8. Inaba K, et al. Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells. J Exp Med 1998;188:2163-2173.
9. 9. Wu T-C, et al. Engineering an intracellular pathway for MHC class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671-11675.
10. 10. Sanderson S, Frauwirth K, Shastri N. Expression of endogenous peptide-MHC class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci USA 1995;92:7217-7221.
11. 11. van Bergen J, Schoenberger SP, Verreck F, Amons R, Offringa R, Koning F. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci USA 1997;94:7499-7502.
12. 12. Ignatowicz L, Winslow G, Bill J, Kappler J, Marrack P. Cell surface expression of MHC class II proteins bound by a single peptide. J Immunol 1995;154:3852-3862.
13. 13. Nakano N, Rooke R, Benoist C, Mathis D. Positive selection of T cells induced by viral delivery of neopeptides to the thymus. Science 1997;275:678-683.
14. 14. Lanzavecchia A. Antigen uptake and accumulation in antigen-specific B cells. Immunol Rev 1987;99:39-51.
15. 15. Lanzavecchia A. Antigen-specific interactions between T and B cells. Nature 1985;314:537-539.
16. 16. Jiang W, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995;375:151-155.
17. 17. Daha MR, van Es LA. Fc- and complement receptor-dependent degradation of soluble immune complexes and stable immunoglobulin aggregates by guinea pig monocytes, peritoneal macrophages and Kupffer cells. J Leukoc Biol 1984;36:569-579.
18. 18. Celis E, Zurawsky VR, Chang TW. Regulation of T cell function by antibodies: enhancement of the response of human T cell clones to hepatitis B surface antigen by antigen-specific monoclonal antibodies. Proc Natl Acad Sci USA 1984;81:6846-6850.
19. 19. Celis E, Chang TW. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science 1984;224:297-299.
20. 20. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured dendritic cells is maintained by GM-CSF plus IL-4 and downregulated by TNFα J Exp Med 1994;179:1109-1118.
21. 21. Cohen BE, Rosenthal AS, Paul WE. Antigen-macrophage interaction. II. Relative roles of cytophilic antibodies and other membrane sites. J Immunol 1973;111:820-828.
22. 22. Manca F, Fenoglio D, Li Pira G, Kunkl A, Celada F. Effect of antigen/antibody ratio on macrophage uptake, processing and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med 1991;173:37-48.
23. 23. Watts C, Lanzavecchia A. Suppressive effect of antibody on processing of T cell epitopes. J Exp Med 1993;178:1459-1463.
24. 24. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II MHC presentation of different T cell determinants. J Exp Med 1995;181:1957-1963.
25. 25. Amigorena S, Lankar D, Briken V, Gapin L, Viguier M, Bonnerot C. Type II and II receptors for IgG control the presentation of different T cell epitopes from single IgG-complexed antigens. J Exp Med 1998;187:1-11.
26. 26. Fraser I, Koziel H, Ezekowitz RA. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition receptors that link innate and adaptive immunity. Semin Immunol 1998;10:363-372.
27. 27. Stahl P. The mannose receptor and other macrophage lectins. Curr Opin Immunol 1992;4:49-52.
28. 28. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med 1990;172:1785-1794.
29. 29. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJM. Specific T helper cell requirement for optimal induction of CTLs against MHC class II negative tumors. J Exp Med 1998;187:693-702.
30. 30. Albert ML, et al. Immature dendritic cells phagocytose apoptotic cells via αβς and CD36, and cross-present antigens to CTL. J Exp Med 1998;188:1359-1368.
31. 31. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
32. 32. Rovere P, et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998;161:4467-4471.
33. 33. Bellone M, et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997;159:5391-5399.
34. 34. Celluzi C, Falo LD. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998;160:3081-3085.
35. 35. Ochsenbein AF, et al. Immune surveillance against a soluble tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999;96:2233-2238.
36. 36. Ravetch JV. Fc receptors: rubor redux. Cell 1994;78:553-560.
37. 37. Fearon DT, Carter RH. The CD19/CR2 /TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995;13:127-149.
38. 38. Yamamoto Y, Klein TW, Friedman H. Involvement of mannose receptor in cytokine IL-1β, IL-6, and GM-CSF responses, but not in chemokine MIP-1β, MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages. Infect Immun 1997;65:1077-1082.
39. 39. Garner RE, Rubanowice K, Sawyer RT, Hudson JA. Secretion of TNF-α by alveolar macrophages in response to Candida albicans mannan. J Leukoc Biol 1994;55:161-168.
40. 40. Stein ML, Gordon S. Regulation of TNF release by murine peritoneal macrophages: role of cell stimulation and specific phagocytic plasma membrane receptors. Eur J Immunol 1991;21:431-437.
41. 41. Shibata Y, Metzger WJ, Myrvik QN. Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J Immunol 1997;159:2462-2467.
42. 42. Ji H, Chang EY, Lin K-Y, Kurman RJ, Pardoll DM, Wu T-C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing HPV16 E7 oncoprotein. Int J Cancer 1998;78:41-45.
43. 43. Lin K-Y, et al. Treatment of established tumors with a novel vaccine that enhances MHC class II presentation of tumor antigen. Cancer Res 1996;56:21-26.
44. 44. Armstrong TD, Pulaski BA, Ostrand-Rosenberg S. Tumor antigen presentation: changing the rules. Cancer Immunol Immunother 1998;46:70-74.
45. 45. Armstrong TD, Clements VK, Martin BK, Ting JPY, Ostrand-Rosenberg S. MHC class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997;94:6886-6891.
46. 46. Fremont DH, Hendrickson WA, Marrack P, Kappler J. Structures of an MHC class II molecule with covalently bound single peptides. Science 1996;272:1001-1004.
47. 47. Lamb JR, Eckels DD, Lake P. Woody JN, Green N. Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature 1982;300:66-69.
48. 48. Stumptner P, Benaroch P. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. EMBO J 1997;16:5807-5818.
49. 49. Newcomb JR, Carboy-Newcomb C, Cresswell P. Trimeric interactions of the invariant chain and its association with MHC class II αβ dimers. J Biol Chem 1996;271:24249-24256.
50. 50. Iwashiro M, et al. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol 1993;67:4533-4542.
51. 51. Wedderburn LR, Searle SJM, Rees AR, Lamb JR, Owen MJ. Mapping T cell recognition: the identification of a T cell receptor residue critical to the specific interaction with an influenza hemagglutinin peptide. Eur J Immunol 1995;25: 1654-1662.
52. 52. Teresa De Magistris M, et al. Antigen analog-MHC act as antagonists of the T cell receptor. Cell 1992;68:625-34.
53. 53. van Elsas A, et al. Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological charactrization of a melanoma vaccine. J Immunother 1997;20:343-53.
54. 54. Geluk A, et al. Functional analysis of DR17 (3) restricted mycobacterial T cell epitopes reveals DR17 binding motif and enables the design of allele-specific competitor peptides. J Immunol 1992;149:2864-71.
55. 55. Ten Bosch GJA, et al. A BCR-ABL oncoprotein p210 b2a2 fusion region sequence is recognized by HLA-DR2 retrsicted CTL and presented by HLA-DR matched cells transfected with an Ii-b2a2 construct. Blood 1999;94:1038-1045.